Theravance Biopharma, Inc. (TBPH) and Mylan N.V. (MYL) said Thursday that positive new data from multiple studies of Yupelri, or revefenacin inhalation solution were presented at the 2018 CHEST annual meeting, held in San Antonio, Texas from October 6 to 10, 2018.
from RTT - Biotech https://ift.tt/2A4I0xA
via IFTTT
No comments:
Post a Comment